Position in BIOA
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$3,473,017
+$565,760 QoQ
Shares Held
141,698
-14.8% QoQ
Ownership
0.309%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#46
of 151 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in BIOA Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Ensign Peak Advisors, Inc holds $86,377,339 across 19 Drug Manufacturers - Specialty & Generic names. BIOA ranks #6 (4.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NBIX |
Neurocrine Biosciences Inc
|
175,946 | $29,653,938 | |
| 2 | ALKS |
Alkermes plc.
|
335,208 | $17,564,899 | |
| 3 | UTHR |
UNITED THERAPEUTICS Corp
|
26,450 | $14,331,403 | |
| 4 | ZTS |
Zoetis Inc.
|
126,706 | $9,105,093 | |
| 5 | AMLX |
Amylyx Pharmaceuticals, Inc.
|
305,441 | $5,485,720 | |
| 6 | BIOA |
BioAge Labs, Inc.
This page
|
141,698 | $3,473,017 | |
| 7 | ELAN |
Elanco Animal Health Inc
|
95,081 | $2,339,943 | |
| 8 | TEVA |
Teva Pharmaceutical Industries Ltd
|
40,850 | $1,383,998 |
All Filings in BIOA
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3,473,017 | 141,698 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $2,907,257 | 166,224 | Shares | Sole | 2026-05-13 | |
| No filing history on record for this holder in this stock. | ||||||